CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.
Home/Biomarker

VHL mutation / loss

Gene: VHL · Type: mutation

Indications: Renal cell carcinoma, VHL disease

SensitivityResistanceCIViC Context

FDA Sensitivity Assertions

DrugIndicationRecommendationFDA SourceLink
BelzutifanRenal cell carcinoma, VHL diseaseINDICATED
FDA Label
Label